CoreCap Advisors’s Outset Medical OM Stock Holding History

CoreCap Advisors’s Portfolio OM Stock Details OM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$2K	–	1575
2021 Q4	$2K	Buy	+3	New	+$2.22K	﹤0.01%	1979

Other funds holding OM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CoreCap Advisors's OM Position: Q1 2022 in Review

CoreCap Advisors sold out of Outset Medical (OM) in Q1 2022, closing a stake of 3 shares — an estimated $2K sold.

CoreCap Advisors first reported a position in OM in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 152 funds tracked by Wall St. Rank hold OM as of Q1 2022.

CoreCap Advisors reported no remaining Outset Medical position as of Q1 2022 after selling out during the quarter.
CoreCap Advisors sold 3 Outset Medical shares in Q1 2022, an estimated $2K.
CoreCap Advisors first reported a position in Outset Medical in Q4 2021 and held it in 1 quarter.
CoreCap Advisors's Outset Medical position peaked at $2K in Q4 2021.
152 funds tracked by Wall St. Rank held Outset Medical as of Q1 2022.

Based on CoreCap Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.